News | July 23, 2009

St. Jude Medical Completes European Enrollment in its Trifecta Stented Tissue Valve Trial

July 23, 2009 – St. Jude Medical Inc. this week said it completed enrollment in its European clinical trial to evaluate Trifecta, a stented pericardial tissue aortic valve.

The Trifecta clinical trial is a multicenter, prospective study, which enrolled 120 patients at six centers throughout Europe. The trial will evaluate the safety and efficacy of the Trifecta stented tissue valve. Efficacy will be determined by the valve’s hemodynamic performance at 12 months.

An estimated 500,000 people worldwide suffer from severe, symptomatic aortic stenosis, while approximately 170,000 patients worldwide undergo aortic tissue heart valve replacements annually. Aortic valve replacement is typically indicated for patients with aortic stenosis, a narrowing of the aortic valve, or aortic regurgitation, a condition in which the valve does not close properly, allowing blood to flow back into the left ventricle.

For more information: www.sjm.com

Related Content

New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Overlay Init